SM
ABUS icon

Sabby Management’s Arbutus Biopharma ABUS Stock Holding History

Sabby Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,311
Closed -$472K – 165
2017
Q2 		$472K Buy
1,311
+996
+316% +$3.43K 0.03% 143
2017
Q1 		$102K Sell
315
-1,718
-85% -$4.77K 0.01% 238
2016
Q4 		$498K Buy
2,033
+84
+4% +$244 0.03% 198
2016
Q3 		$670K Buy
1,949
+1,280
+191% +$5K 0.03% 208
2016
Q2 		$233K Buy
669
+39
+6% +$165 0.01% 241
2016
Q1 		$260K Buy
630
+279
+79% +$997 0.01% 248
2015
Q4 		$156K Sell
351
-436
-55% -$2.39K 0.01% 290
2015
Q3 		$479K Buy
787
+130
+20% +$1.15K 0.02% 295
2015
Q2 		$779K Buy
+657
New +$10K 0.03% 232
2014
Q4 		– Sell
-883
Closed -$1.87K – 237
2014
Q3 		$1.87K Buy
+883
New +$14.4K 0.07% 114
2014
Q2 		– Sell
-450
Closed -$967K – 254
2014
Q1 		$967K Buy
+450
New +$8.09K 0.05% 136

Other funds holding ABUS

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Sabby Management's ABUS Position: Q3 2017 in Review

Sabby Management sold out of Arbutus Biopharma (ABUS) in Q3 2017, closing a stake of 248,600 shares — an estimated $895K sold.

Sabby Management first reported a position in ABUS in Q4 2013 and held it in 11 quarters. The position peaked at $4.95M in Q1 2016. 53 funds tracked by Wall St. Rank hold ABUS as of Q3 2017.

  • Sabby Management reported no remaining Arbutus Biopharma position as of Q3 2017 after selling out during the quarter.
  • Sabby Management sold 248,600 Arbutus Biopharma shares in Q3 2017, an estimated $895K.
  • Sabby Management first reported a position in Arbutus Biopharma in Q4 2013 and held it in 11 quarters.
  • Sabby Management's Arbutus Biopharma position peaked at $4.95M in Q1 2016.
  • 53 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2017.

Based on Sabby Management's 13F filing for Q3 2017, filed 14 Nov 2017.